Results 41 to 50 of about 259,058 (180)
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto +9 more
wiley +1 more source
This study developed a two‐stage model using radiomics‐based multiparametric MRI and clinical indicators to help identify and grade clinically significant prostate cancer. The model showed promising levels of diagnostic accuracy and predictive performance.
Yuyan Zou +10 more
wiley +1 more source
Association of different types of androgen deprivation therapy with bone health.
Association of different types of androgen deprivation therapy with bone health.
Kwan Lun Ho (3716626) +13 more
core +1 more source
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan +4 more
wiley +1 more source
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek +3 more
wiley +1 more source
Contemporary role of androgen deprivation therapy for prostate cancer [PDF]
Androgen deprivation therapy (ADT) for prostate cancer (PCa) represents one of the most effective systemic palliative treatments known for solid tumors.
Pagliarulo, Vincenzo +24 more
core +1 more source
Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
The recommended treatment for high-risk localized or locally advanced prostate cancer is radical prostatectomy plus extended pelvic lymph node dissection or radiation therapy plus long-term androgen deprivation therapy. However, some patients are treated
Hiroaki Iwamoto +3 more
core +1 more source
ABSTRACT Triple‐negative breast cancer (TNBC) represents the most aggressive subtype with limited therapeutic options and the poorest clinical outcomes. Using high‐resolution nUPLC‐QTOF‐MS/MS, we performed comprehensive proteomic profiling of TNBC cell lines representing disease progression stages: HCC‐1937 (stage IIB), HCC‐1599 (stage IIIA), and MDA ...
Claudia Sissely Chaviano‐Montes de Oca +7 more
wiley +1 more source
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang +7 more
wiley +1 more source
Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes
Hamed Ahmadi, Siamak Daneshmand Institute of Urology, University of Southern California, Los Angeles, CA, USA Abstract: Androgen deprivation therapy (ADT) constitutes the first-line treatment for patients with locally advanced tumors, recurrent or ...
Ahmadi H, S, Daneshm
core

